Literature DB >> 27155899

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.

Xiaokai Li1, Jiayi Shen1, Li Tan2, Zhang Zhang3, Donglin Gao2, Jinfeng Luo3, Huimin Cheng3, Xiaoping Zhou1, Jie Ma1, Ke Ding4, Xiaoyun Lu5.   

Abstract

B-Raf(V600E) was an effective target for the treatment of human cancers. Based on a pan-Raf inhibitor TAK-632, a series of N-(4-aminopyridin-2-yl)amide derivatives were designed as novel B-Raf(V600E) inhibitors. Detailed structure-activity studies of the compounds revealed that most of the compounds displayed potent enzymatic activity against B-Raf(V600E), and good selectivity over B-Raf(WT). One of the most promising compound 4l exhibited potent inhibitory activity with an IC50 value of 38nM for B-raf(V600E), and displayed antiproliferative activities against colo205 and HT29 cells with IC50 values of 0.136 and 0.094μM, respectively. It also displayed good selectivity on both enzymatic and cellular assays over B-Raf(WT). These inhibitors may serve as lead compounds for further developing novel B-Raf(V600E) inhibitors as anticancer drugs.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B-Raf(V600E) inhibitor; N-(4-Aminopyridin-2-yl)amides; Selective; Structural modification

Mesh:

Substances:

Year:  2016        PMID: 27155899     DOI: 10.1016/j.bmcl.2016.04.076

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells.

Authors:  Yingjun Li; Yongjun Huang; Huimin Cheng; Fang Xu; Ruxi Qi; Botao Dai; Yujian Yang; Zhengchao Tu; Lijie Peng; Zhang Zhang
Journal:  Front Chem       Date:  2022-07-22       Impact factor: 5.545

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.